GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Altman Z-Score

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Altman Z-Score : -23.55 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -23.55 is in distress zone. This implies bankruptcy possibility in the next two years.

IPI Legacy Liquidation Co has a Altman Z-Score of -23.55, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for IPI Legacy Liquidation Co's Altman Z-Score or its related term are showing as below:

IMPLQ' s Altman Z-Score Range Over the Past 10 Years
Min: -23.55   Med: -5.46   Max: 0.81
Current: -23.55

During the past 4 years, IPI Legacy Liquidation Co's highest Altman Z-Score was 0.81. The lowest was -23.55. And the median was -5.46.


IPI Legacy Liquidation Co Altman Z-Score Historical Data

The historical data trend for IPI Legacy Liquidation Co's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Altman Z-Score Chart

IPI Legacy Liquidation Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Altman Z-Score
- - -1.91 -7.20

IPI Legacy Liquidation Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.46 -7.20 -11.61 -18.86 -23.51

Competitive Comparison of IPI Legacy Liquidation Co's Altman Z-Score

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IPI Legacy Liquidation Co's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Altman Z-Score falls into.



IPI Legacy Liquidation Co Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

IPI Legacy Liquidation Co's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-2.8887+1.4*-10.6164+3.3*-1.765+0.6*0.0028+1.0*0.5984
=-23.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $35.07 Mil.
Total Current Assets was $23.43 Mil.
Total Current Liabilities was $124.74 Mil.
Retained Earnings was $-372.35 Mil.
Pre-Tax Income was -13.814 + -7.357 + -30.067 + -23.041 = $-74.28 Mil.
Interest Expense was -3.661 + -3.015 + -2.933 + -2.766 = $-12.38 Mil.
Revenue was 5.023 + 6.584 + 4.372 + 5.008 = $20.99 Mil.
Market Cap (Today) was $0.36 Mil.
Total Liabilities was $126.98 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(23.427 - 124.743)/35.073
=-2.8887

X2=Retained Earnings/Total Assets
=-372.348/35.073
=-10.6164

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-74.279 - -12.375)/35.073
=-1.765

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.359/126.978
=0.0028

X5=Revenue/Total Assets
=20.987/35.073
=0.5984

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

IPI Legacy Liquidation Co has a Altman Z-Score of -23.55 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


IPI Legacy Liquidation Co  (OTCPK:IMPLQ) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


IPI Legacy Liquidation Co Altman Z-Score Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb officer: CFO 24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin officer: VP, Controller & Interim CFO C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson director 1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams director, officer: COB, CEO and President C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp 10 percent owner 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019